Coronary angioplasty performed within the thrombolysis in Myocardial Infarction II study

Area of Science:

• Cardiology
• Interventional Cardiology
• Thrombolytic Therapy

Background:

• A significant number of myocardial infarction patients undergo percutaneous transluminal coronary angioplasty (PTCA) after thrombolytic therapy.
• The Thrombolysis In Myocardial Infarction (TIMI) II study provides data on PTCA outcomes following recombinant tissue-type plasminogen activator (rt-PA).

Purpose of the Study:

• To evaluate the outcomes of percutaneous transluminal coronary angioplasty (PTCA) performed after recombinant tissue-type plasminogen activator (rt-PA) administration in myocardial infarction patients.
• To identify clinical and anatomical factors associated with adverse outcomes following PTCA in this patient cohort.

Main Methods:

• Analysis of data from 1,414 patients who underwent PTCA within 42 days of rt-PA administration in the TIMI II study.
• Multivariate analysis to determine risk ratios for adverse events based on patient characteristics and procedural timing.

Main Results:

• Primary angiographic success was achieved in 88.7% of patients.
• Adverse outcomes within 1 year (death, reinfarction, further revascularization) occurred in 25.1% of patients.
• Increased risk for unsuccessful PTCA was noted in patients treated within 2 hours of rt-PA and those over 70.
• Multivessel disease and prior angina were associated with increased risk for revascularization and mortality/recurrent infarction.

Conclusions:

• PTCA following rt-PA in myocardial infarction has generally favorable results but carries risks.
• Specific patient subgroups, including those with multivessel disease, prior angina, older age, and early PTCA timing, are at higher risk.
• These findings serve as a benchmark for evaluating PTCA outcomes in myocardial infarction patients treated with thrombolysis.